Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies

NCT04537715 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT04537715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04537715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies
Lead sponsor
Epizyme, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 23, 2020
Completion date
April 3, 2023
Enrollment
42 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, all malignancies, diffuse large b-cell lymphoma (dlbcl), epithelioid sarcoma (es), follicular lymphoma (fl), hematologic malignancy, mesothelioma, non-hodgkin lymphoma (nhl), renal medullary carcinoma, rhabdoid tumor, solid tumor, synovial sarcoma